Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Mallinckrodt
Baxter
Express Scripts
AstraZeneca

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GENGRAF

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for Gengraf

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00057954 Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma Terminated National Cancer Institute (NCI) Phase 2 2005-06-01 RATIONALE: Photopheresis allows patient white blood cells to be treated with ultraviolet (UV) light and drugs outside the body to inactivate T cells. Pentostatin may suppress the immune system and reduce the chance of developing graft-versus-host disease (GVHD) following bone marrow transplantation. Combining photopheresis with pentostatin and total-body irradiation may be effective in killing cancer cells before bone marrow transplantation. PURPOSE: This phase II trial is studying how well giving photophoresis together with pentostatin and total-body irradiation as a reduced-intensity regimen before allogeneic bone marrow transplantation works in treating patients with relapsed non-Hodgkin's or Hodgkin's lymphoma.
NCT00057954 Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma Terminated Eastern Cooperative Oncology Group Phase 2 2005-06-01 RATIONALE: Photopheresis allows patient white blood cells to be treated with ultraviolet (UV) light and drugs outside the body to inactivate T cells. Pentostatin may suppress the immune system and reduce the chance of developing graft-versus-host disease (GVHD) following bone marrow transplantation. Combining photopheresis with pentostatin and total-body irradiation may be effective in killing cancer cells before bone marrow transplantation. PURPOSE: This phase II trial is studying how well giving photophoresis together with pentostatin and total-body irradiation as a reduced-intensity regimen before allogeneic bone marrow transplantation works in treating patients with relapsed non-Hodgkin's or Hodgkin's lymphoma.
NCT00983424 Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer Completed Avon Foundation Phase 1 2010-02-01 The purpose of this research study is to evaluate the safety of therapy with nab-paclitaxel and CsA and if the addition of Cyclosporine A (CsA) to nab-paclitaxel helps stop cancer cells as well as or better than nab-paclitaxel alone.
NCT00983424 Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer Completed Northwestern University Phase 1 2010-02-01 The purpose of this research study is to evaluate the safety of therapy with nab-paclitaxel and CsA and if the addition of Cyclosporine A (CsA) to nab-paclitaxel helps stop cancer cells as well as or better than nab-paclitaxel alone.
NCT01106833 Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Active, not recruiting Blood and Marrow Transplant Clinical Trials Network Phase 2/Phase 3 2010-04-01 This study is designed as a combined Phase II/III, randomized, open label, multicenter, prospective comparative study of sirolimus plus prednisone versus sirolimus/calcineurin-inhibitor plus prednisone for the treatment of chronic GVHD. Patients will be stratified by transplant center and will be randomized to an experimental arm of one of the two pre-specified experimental arms (sirolimus + prednisone or the comparator arm of sirolimus + calcineurin inhibitor + prednisone) in a 1:1 ratio.
NCT01106833 Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Active, not recruiting National Cancer Institute (NCI) Phase 2/Phase 3 2010-04-01 This study is designed as a combined Phase II/III, randomized, open label, multicenter, prospective comparative study of sirolimus plus prednisone versus sirolimus/calcineurin-inhibitor plus prednisone for the treatment of chronic GVHD. Patients will be stratified by transplant center and will be randomized to an experimental arm of one of the two pre-specified experimental arms (sirolimus + prednisone or the comparator arm of sirolimus + calcineurin inhibitor + prednisone) in a 1:1 ratio.
NCT01106833 Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Active, not recruiting National Heart, Lung, and Blood Institute (NHLBI) Phase 2/Phase 3 2010-04-01 This study is designed as a combined Phase II/III, randomized, open label, multicenter, prospective comparative study of sirolimus plus prednisone versus sirolimus/calcineurin-inhibitor plus prednisone for the treatment of chronic GVHD. Patients will be stratified by transplant center and will be randomized to an experimental arm of one of the two pre-specified experimental arms (sirolimus + prednisone or the comparator arm of sirolimus + calcineurin inhibitor + prednisone) in a 1:1 ratio.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gengraf

Condition Name

Condition Name for Gengraf
Intervention Trials
Recurrent Hodgkin Lymphoma 3
Chronic Myelomonocytic Leukemia 3
Myelodysplastic Syndrome 3
Acute Myeloid Leukemia in Remission 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Gengraf
Intervention Trials
Lymphoma 5
Leukemia 4
Precursor Cell Lymphoblastic Leukemia-Lymphoma 4
Myelodysplastic Syndromes 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Gengraf

Trials by Country

Trials by Country for Gengraf
Location Trials
United States 35
China 1
Malaysia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Gengraf
Location Trials
Washington 5
California 2
Illinois 2
Ohio 2
New Jersey 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Gengraf

Clinical Trial Phase

Clinical Trial Phase for Gengraf
Clinical Trial Phase Trials
Phase 4 1
Phase 2/Phase 3 1
Phase 2 6
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Gengraf
Clinical Trial Phase Trials
Not yet recruiting 4
Recruiting 3
Completed 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Gengraf

Sponsor Name

Sponsor Name for Gengraf
Sponsor Trials
National Cancer Institute (NCI) 7
Fred Hutchinson Cancer Research Center 4
Blood and Marrow Transplant Clinical Trials Network 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Gengraf
Sponsor Trials
Other 16
NIH 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Baxter
Moodys
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.